Dataset Information

Dynamics and control of COVID-19 pandemic with nonlinear incidence rates.

ABSTRACT: World Health Organization (WHO) has declared COVID-19 a pandemic on March 11, 2020. As of May 23, 2020, according to WHO, there are 213 countries, areas or territories with COVID-19 positive cases. To effectively address this situation, it is imperative to have a clear understanding of the COVID-19 transmission dynamics and to concoct efficient control measures to mitigate/contain the spread. In this work, the COVID-19 dynamics is modelled using susceptible-exposed-infectious-removed model with a nonlinear incidence rate. In order to control the transmission, the coefficient of nonlinear incidence function is adopted as the Governmental control input. To adequately understand the COVID-19 dynamics, bifurcation analysis is performed and the effect of varying reproduction number on the COVID-19 transmission is studied. The inadequacy of an open-loop approach in controlling the disease spread is validated via numerical simulations and a robust closed-loop control methodology using sliding mode control is also presented. The proposed SMC strategy could bring the basic reproduction number closer to 1 from an initial value of 2.5, thus limiting the exposed and infected individuals to a controllable threshold value. The model and the proposed control strategy are then compared with real-time data in order to verify its efficacy.

SUBMITTER: Rohith G

PROVIDER: S-EPMC7315126 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Dynamics and control of COVID-19 pandemic with nonlinear incidence rates.

Rohith G G Devika K B KB

Nonlinear dynamics 20200625 3

World Health Organization (WHO) has declared COVID-19 a pandemic on March 11, 2020. As of May 23, 2020, according to WHO, there are 213 countries, areas or territories with COVID-19 positive cases. To effectively address this situation, it is imperative to have a clear understanding of the COVID-19 transmission dynamics and to concoct efficient control measures to mitigate/contain the spread. In this work, the COVID-19 dynamics is modelled using susceptible-exposed-infectious-removed model with ...[more]

PMID: 32836807

Similar Datasets

Project description:BackgroundThe COVID-19 pandemic caused an abrupt drop in in-person health care (inpatient, Emergency Department, outpatient) and an increase in telehealth care, which poses challenges in vaccine safety studies that identify outcomes from in-person encounters. We examined the changes in incidence rates of selected encounter-based outcomes during the COVID-19 pandemic.MethodsWe assembled a cohort of members from 8 Vaccine Safety Datalink sites from January 1, 2017 through December 31, 2020. Using ICD-10 diagnosis codes or laboratory criteria, we identified 21 incident outcomes in traditional in-person settings and all settings. We defined 4 periods in 2020: January-February (pre-pandemic), April-June (early pandemic), July-September (middle pandemic), and October-December (late pandemic). We defined four corresponding periods in each year during 2017-2019. We calculated incidence rates, conducted difference in difference (DiD) analyses, and reported ratios of incidence rate ratios (RRR) to examine changes in rates from pre-pandemic to early, middle, and late pandemic in 2020, after adjusting for changes across similar periods in 2017-2019.ResultsAmong > 10 million members, regardless of setting and after adjusting for changes during 2017-2019, we found that incidence rates of acute disseminated encephalomyelitis, encephalitis/myelitis/encephalomyelitis/meningoencephalitis, and thrombotic thrombocytopenic purpura did not significantly change from the pre-pandemic to early, middle or late pandemic periods (p-values ≥ 0.05). Incidence rates decreased from the pre-pandemic to early pandemic period during 2020 for acute myocardial infarction, anaphylaxis, appendicitis, Bell's palsy, convulsions/seizures, Guillain-Barré syndrome, immune thrombocytopenia (ITP), narcolepsy/cataplexy, hemorrhagic stroke, ischemic stroke, and venous thromboembolism (p-values < 0.05). Incidence rates of Bell's palsy, ITP, and narcolepsy/cataplexy were higher in all settings than in traditional in-person settings during the three pandemic periods (p-values < 0.05).ConclusionRates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.

Dataset Information

Dynamics and control of COVID-19 pandemic with nonlinear incidence rates.

Publications

Dynamics and control of COVID-19 pandemic with nonlinear incidence rates.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets